Cranial neuropathies in advanced nasopharyngeal carcinoma: Neurological recovery after modern radiotherapy and systemic chemotherapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2021
Historique:
received: 24 05 2021
revised: 31 08 2021
accepted: 31 08 2021
pubmed: 11 9 2021
medline: 31 12 2021
entrez: 10 9 2021
Statut: ppublish

Résumé

Cranial neuropathy is a common presenting symptom of advanced T4 nasopharyngeal carcinoma (NPC). Data on neurological outcomes after modern intensity-modulated radiotherapy (IMRT) and chemotherapy are scarce. Case records of consecutive T4 NPC patients who received definitive IMRT in two tertiary oncology centers in 2004-2019 were reviewed. Patterns of cranial neuropathies at disease presentation were recorded. Time to neurological recovery and the rate of subsequent re-palsy were estimated by the Kaplan-Meier method. Clinical predictors were analyzed using multivariable Cox regression. During the study period, 257 T4 NPC patients presented with 504 individual cranial neuropathies. The median time from neuropathy onset to NPC diagnosis was two months (IQR, 1-4 months). Cranial nerves (CN) VI (56.4%), V2 (47.9%), and V3 (29.2%) were most frequently involved. At a median follow-up of 6.4 years, the crude partial and full recovery rates of neuropathies were 111 (22%) and 289 (57.3%), respectively. CN III, IV, and VI had the highest 5-year full recovery rate (72.7%), followed by CN V1-3 (60.3%), XII (48.6%), and II (18.2%) (p < 0.001). Positive smoking history, optic nerve involvement, and longer duration of neuropathy were independent negative predictors for neurological recovery. After full recovery, re-palsy was observed in 6.9% (20/289) of the nerves, 60% of which co-occurred with local NPC recurrences. Durable recovery of most cranial neuropathies in advanced T4 NPC was observed in the era of modern IMRT and effective systemic chemotherapy. Both patient and disease factors affected the chance of neurological recovery. Re-palsy of recovered nerves should prompt careful evaluation for local recurrence.

Identifiants

pubmed: 34506830
pii: S0167-8140(21)06716-5
doi: 10.1016/j.radonc.2021.08.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

221-228

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

James C H Chow (JCH)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Anna Lee (A)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

Kelvin K H Bao (KKH)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

K M Cheung (KM)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Jeffrey C H Chan (JCH)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Anthony H P Tam (AHP)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Winnie W Y Sung (WWY)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Therese Y M Tsui (TYM)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Elizabeth Y H Chuk (EYH)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Daniel H S Chung (DHS)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

K H Wong (KH)

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China.

Anussara Prayongrat (A)

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Chawalit Lertbutsayanukul (C)

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Danita Kannarunimit (D)

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Chakkapong Chakkabat (C)

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Sarin Kitpanit (S)

Division of Radiation Oncology, Department of Radiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. Electronic address: sarin.k@chula.ac.th.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH